NEW YORK (GenomeWeb) – Rosetta Genomics announced after the close of the market Wednesday a more than 400 percent jump in fourth quarter revenues as the company benefitted from an expanded suite of molecular diagnostic offerings.

For the three-month period ended Dec. 31, Rosetta's revenues climbed to $3.6 million, including $1.6 million in license revenue, from $698,000, which included $228,000 in license revenue, in the same period a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.